Sarepta Therapeutics's total assets for Q1 2025 were $3.47B, a decrease of -12.56% from the previous quarter. SRPT total liabilities were $2.32B for the fiscal quarter, a -4.63% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.